Corcept Therapeutics Incorporated (CORT) announced data from the phase II DAZALS study evaluating its selective cortisol modulator, dazucorilant, for treating patients with amyotrophic lateral sclerosis (ALS), a degenerative neurologic disorder.The double-blind, placebo-controlled DAZALS study evaluated two doses of dazucorilant (150 mg and 300 mg) for treating patients with ALS.The study did not meet its primary endpoint, which was the change from baseline in the ALS Functional Rating Scale-Revised (ALSFRS ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.Zacks Premium includes access to the Zacks Style Scores as well. What are the Zacks Style Sco ...

A month has gone by since the last earnings report for Corcept Therapeutics (CORT) . Shares have added about 19.7% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Corcept due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts. Corcept Beats Q3 Earnings & Sales Estimates, ...

Welcome to my profile!My name is Vincent. I have over three years of experience as a tech-oriented buy-side analyst at a major bank, where I co-managed U.S. equity portfolios with over $700M in assets under management. I’ve worked across both large-cap and small-cap stocks, gaining a deep understanding of financial markets. Fascinated by innovation and its potential, my goal is not only to identify tomorrow's future leaders but also to share and discuss these insights with you.I believe every investor shoul ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.Zacks Premium also includes the Zacks Style Scores. What are the Zacks Style Scores? The Za ...

Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and produce exceptional returns. However, it isn't easy to find a great growth stock.That's because, these stocks usually carry above-average risk and volatility. In fact, betting on a stock for which the growth story is actually over or nearing its end could lead to significant loss.However, it's pretty easy to find cutting-edge growth stocks with the help of the Zacks Gro ...

Corcept Therapeutics (CORT) closed the last trading session at $54.31, gaining 11% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $74.90 indicates a 37.9% upside potential.The mean estimate comprises five short-term price targets with a standard deviation of $5.03. While the lowest estimate of $67 indicates a 23.4% increase from the current price level, the most optimistic analyst ...

When it comes to short-term investing or trading, they say "the trend is your friend." And there's no denying that this is the most profitable strategy. But making sure of the sustainability of a trend to profit from it is easier said than done.The trend often reverses before exiting the trade, leading to a short-term capital loss for investors. So, for a profitable trade, one should confirm factors such as sound fundamentals, positive earnings estimate revisions, etc. that could keep the momentum in the st ...

For Immediate ReleaseChicago, IL – November 11, 2024 – Today, Zacks Equity Research like Madrigal Pharmaceuticals (MDGL) , Corcept Therapeutics (CORT) , Catalyst Pharmaceuticals (CPRX) , Larimar Therapeutics (LRMR) and Theravance Biopharma (TBPH) .Industry: Small PharmaLink: https://www.zacks.com/commentary/2367138/5-small-drug-stocks-to-buy-as-trump-gets-re-elected?art_rec=quote-stock_overview-zacks_news-ID01-txt-2367138The drug industry witnessed major policy changes during Joe Biden's four-year term as U ...

The drug industry witnessed major policy changes during Joe Biden's four-year term as U.S. President, including the historic Inflation Reduction Act (“IRA”). With Donald Trump’s reelection, the biotech industry hopes to witness more innovation and mergers and acquisitions (M&A) activity. Efforts to repeal the IRA look likely. However, it all depends on who is appointed to key roles at federal health agencies. Drug pricing reforms are expected to remain a key priority for the new government. Trump, in his pr ...